Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Sells $228,560.00 in Stock

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) SVP Joseph R. Young sold 5,714 shares of the company's stock in a transaction that occurred on Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total value of $228,560.00. Following the completion of the sale, the senior vice president now owns 53,171 shares in the company, valued at $2,126,840. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vera Therapeutics Stock Down 1.7 %

NASDAQ:VERA traded down $0.85 during trading hours on Friday, hitting $47.97. 2,165,985 shares of the company traded hands, compared to its average volume of 1,317,356. The company has a quick ratio of 7.71, a current ratio of 7.71 and a debt-to-equity ratio of 0.49. The firm's 50-day simple moving average is $43.39 and its 200-day simple moving average is $24.98. Vera Therapeutics, Inc. has a one year low of $6.05 and a one year high of $50.78. The company has a market cap of $2.61 billion, a PE ratio of -20.95 and a beta of 1.05.

Wall Street Analyst Weigh In

A number of research firms have issued reports on VERA. Wedbush increased their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a "neutral" rating in a report on Thursday, March 21st. Cantor Fitzgerald began coverage on Vera Therapeutics in a report on Monday, January 8th. They set an "overweight" rating on the stock. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of Vera Therapeutics in a report on Wednesday, December 27th. Raymond James raised Vera Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $29.00 to $37.00 in a research report on Friday, January 26th. Finally, Guggenheim reiterated a "buy" rating and issued a $56.00 target price on shares of Vera Therapeutics in a report on Friday, April 5th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Vera Therapeutics currently has an average rating of "Buy" and an average target price of $32.29.

Hedge Funds Weigh In On Vera Therapeutics

Several large investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC raised its stake in shares of Vera Therapeutics by 810.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company's stock worth $38,000 after purchasing an additional 4,303 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of Vera Therapeutics by 163.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company's stock worth $45,000 after purchasing an additional 1,731 shares during the period. UBS Group AG bought a new stake in shares of Vera Therapeutics during the 1st quarter worth $47,000. Royal Bank of Canada raised its stake in shares of Vera Therapeutics by 94.8% during the 2nd quarter. Royal Bank of Canada now owns 3,339 shares of the company's stock worth $54,000 after purchasing an additional 1,625 shares during the period. Finally, Amalgamated Bank raised its stake in shares of Vera Therapeutics by 26.0% during the 3rd quarter. Amalgamated Bank now owns 4,189 shares of the company's stock worth $57,000 after purchasing an additional 864 shares during the period. 99.21% of the stock is currently owned by institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.